About Centessa Pharmaceuticals
Centessa Pharmaceuticals is a publicly listed company based in Boston (United States) founded in 2021, and was acquired by Lilly in March 2026. Medicines for sleep-wake, neurological, neurodegenerative, and psychiatric disorders are developed. Centessa Pharmaceuticals has raised $250 million across 1 funding round from investors including Lilly, T. Rowe Price and General Atlantic. The company has 77 employees. Centessa Pharmaceuticals has completed 1 acquisition, including Apcintex. Centessa Pharmaceuticals offers products and services including Orexin Receptor 2 Agonist Program and LockBody Technology Platform. Its focus areas include Diversified Pharmaceuticals, Drugs, Life Sciences and Immunology. Its legal entity is CENTESSA PHARMACEUTICALS PLC. Its competitors include Biogen, ADMA Biologics and Kymeratx; 3 of its 3 listed competitors have raised funding.
Company details
Centessa Pharmaceuticals was founded in 2021 and is headquartered in Boston, United States. Medicines targeting sleep-wake disorders, neurological conditions, neurodegenerative diseases, and psychiatric issues are developed within the biotechnology sector. Operations encompass discovery through late-stage development of potential first-in-class and best-in-class therapies for rare diseases and immuno-oncology indications. Efforts are directed toward addressing unmet medical needs across these areas.
- Headquarters Boston, United States
- Employees 77
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website centessa.com
- Social LinkedIn X
- Acquired by Lilly (Mar 2026)
- Legal Name Centessa Pharmaceuticals Plc Adr
Products & Services of Centessa Pharmaceuticals
Centessa Pharmaceuticals offers a comprehensive portfolio of products and services, including Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
Develops agonists for treating sleep-wake and neurological disorders
Enables innovative medicine development for various disorders
Funding Insights of Centessa Pharmaceuticals
Centessa Pharmaceuticals has successfully raised a total of $250M through 1 strategic funding round. The most recent funding activity was a Series A round of $250 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $250M
- Total Rounds 1
- Last Round Series A — $250M
- First Round $250M
(Feb 2021)
- Investors Count 14
All 1 funding rounds of Centessa Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2021 | $250M | Series A | – | General Atlantic, Vida Ventures |
15 investors in total: 15 institutional.
Investors in Centessa Pharmaceuticals
Centessa Pharmaceuticals has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, T. Rowe Price and General Atlantic.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity fund focused on global markets | 1980 | generalatlantic.com | New York, United States | |
Biomedical innovations are transformed into therapies by Vida Ventures. | vidaventures.com | Boston, United States | ||
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Biotech startups are funded by this venture capital firm. | boxercap.com | San Diego, United States | ||
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Healthcare startups are funded by this corporate-backed venture capital entity. | lifesciventure.com | New York, United States | ||
VC & PE firm focused on healthcare sector | venrockcp.com | Palo Alto, United States | ||
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States | ||
Diversified asset management services are provided to investors globally. | 1937 | troweprice.com | Baltimore, United States |
Investor details for Centessa Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Centessa Pharmaceuticals
54 people are tracked at Centessa Pharmaceuticals (37 in leadership, 7 in board & advisors, 10 in team); the tracked headcount is 77.
| Name | Role | Group |
|---|---|---|
Deborah Hartman | Global Scientific Head, Orexin Program | Leadership |
Saurabh Saha | CEO & Director | Leadership |
Samantha Feliz | Director Clinical Operations | Leadership |
David Chao | Chief Administrative Officer | Leadership |
Gregory Weinhoff | Chief Business Officer | Leadership |
Kevin McLaughlin | Sr. Director, Clinical Operations, Early Development | Leadership |
Tia Bush | Chief Technology & Quality Officer | Leadership |
Yong Li | Executive Director, Biostatistics | Leadership |
Tim Graham | Senior Director, Program Management | Leadership |
Karen Anderson | Chief People Officer | Leadership |
John Crowley | Chief Financial Officer | Leadership |
Sankar Subramanian | Director, Process Chemistry | Leadership |
Mandy Sterkel | Executive Director, Clinical Development | Leadership |
Yashar Salek | Executive Director, Clinical Development | Leadership |
Jeff Wald | Executive Director And Head, Clinical Pharmacology | Leadership |
Linda Hook-Dinnocenzo | Vice President GXP Quality Assurance | Leadership |
Sherry Y. | Vp, CMC Biologics | Leadership |
Brian Burleson | Director Of Quality Assurance | Leadership |
Richard M. | Vice President, Controller | Leadership |
Sai Pulukuri | Vice President, Immunooncology, Pharmacology & Translational Science | Leadership |
34 more people are available in the full profile.
Complete people profiles for Centessa Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Centessa Pharmaceuticals
Centessa Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol CNTA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 May 2021
- Listed onNASDAQ: CNTA
- Listed entityCentessa Pharmaceuticals PLC ADR
- Exchange sectorHealth technology
- ISINUS1523091007
- Share price$39.59 (-0.05% on the day) · 2026-05-11
- Market capitalisation$6.13B
- EPS (diluted, trailing year)$-1.77
- Volume (last session)682,355
- Analyst consensusNeutral
Financials of Centessa Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | -$235.9M | -$200.2M | |
| 2023 | $6.9M | -$151.7M | -$171.1M |
| 2022 | -$216.1M | -$210.0M |
Detailed financial statements for Centessa Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Centessa Pharmaceuticals
Centessa Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Apcintex.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Anti-coagulant targeting APC pathway is developed for haemophilia treatment. | apcintex.com | Cambridge, United Kingdom | 2014 | Feb 2021 | •••• |
Complete acquisition details for Centessa Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Centessa Pharmaceuticals
5 dated milestones of Centessa Pharmaceuticals across 5 years, from founding to its latest funding, stage changes and deals.
Competitors of Centessa Pharmaceuticals
Centessa Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Biogen, ADMA Biologics and Kymeratx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| admabiologics.com | 2005 | Ramsey, United States | $17.55M | 498 | Plasma-based biologics are developed for immune deficiency and infectious diseases. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. |
Detailed competitors of Centessa Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Centessa Pharmaceuticals
The website of Centessa Pharmaceuticals (centessa.com) receives about 8.9K visits a month and ranks #2,881,544 among all websites worldwide, #3,860 in Biotechnology and Pharmaceuticals.
- Monthly visits8.9K
▲ 18.9% vs previous month
- Unique visitors3.2K
per month
- Global rank#2,881,544
among all websites
- Category rank#3,860
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.6
- Average visit13 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with Centessa Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| novotech-cro.com | 100% | 49.2K | #897,361 | View details | |
thepharmaletter.com | thepharmaletter.com | 58% | #486,864 | – |
Top companies in Oncology
3 companies that operate in the same segment as Centessa Pharmaceuticals (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Centessa Pharmaceuticals
Complete news archive for Centessa Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Centessa Pharmaceuticals
Centessa Pharmaceuticals was founded in 2021.
Centessa Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Centessa Pharmaceuticals is a funded company, having raised a total of $250M across 1 funding round to date. The company's 1st funding round was a Series A of $250M, raised on Feb 2021.
Centessa Pharmaceuticals has 77 employees.
Centessa Pharmaceuticals was founded in 2021 and is headquartered in Boston, United States. Medicines targeting sleep-wake disorders, neurological conditions, neurodegenerative diseases, and psychiatric issues are developed within the biotechnology sector. Operations encompass discovery through late-stage development of potential first-in-class and best-in-class therapies for rare diseases and immuno-oncology indications. Efforts are directed toward addressing unmet medical needs across these areas.
Centessa Pharmaceuticals's top competitors include ADMA Biologics, Kymeratx and Biogen.
Centessa Pharmaceuticals offers Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
Yes, Centessa Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol CNTA.
Centessa Pharmaceuticals has made 1 acquisition, including Apcintex.
Centessa Pharmaceuticals has 15 investors. Key investors include Lilly, T. Rowe Price, General Atlantic, Janus Henderson Investors, and Vida Ventures.
Centessa Pharmaceuticals operates through Centessa Pharmaceuticals Plc.
Yes. Centessa Pharmaceuticals was acquired by Lilly in March 2026.